Featured Research

from universities, journals, and other organizations

Targeting Sugars May Revolutionize Treatment Of Bone Disorders

Date:
October 10, 2007
Source:
American Chemical Society
Summary:
One of the most fundamental scientific beliefs about the structure of human bone is apparently incomplete -- a finding scientists say could have sweeping impact on treatments for osteoporosis and other bone disorders. Their study concludes that sugars, not proteins, are key organic building blocks that account for bone's toughness and stiffness.

Researchers in the United Kingdom and Germany are reporting that one of the most fundamental scientific beliefs about the structure of human bone is incomplete -- a finding they say could have sweeping impact on treatments for osteoporosis and other bone disorders. Their study concludes that sugars, not proteins, are key organic building blocks that account for bone's toughness and stiffness.

The University of Cambridge's David G. Reid and Melinda Duer and Christian Jaeger at and Federal Institute of Materials Research and Testing in Berlin, explain that scientists have long held that collagen and other proteins were the main organic molecules responsible for stabilizing normal bone structure.

That belief has been the basis for existing medications for bone disorders, and bone replacement materials. At the same time, researchers paid little attention to roles of sugars (carbohydrates) in the complex process of bone growth.

In the new report, researchers describe experiments on mineralization in horse bones using an analysis tool called nuclear magnetic resonance (NMR). They found that sugars, particularly proteoglycans and glycosaminoglycans, appear to play a larger role than proteins in controlling the bone mineralization process and may be a key to maintaining healthy bones.

"This could exert a major impact on the pharmacological management of bone disorders by directing novel therapeutic approaches, as it suggests new molecular targets for drug discovery," the report states. "It also offers new disease biomarkers for diagnosis."

"Organic-Mineral Interface in Bone is Predominately Polysaccharide" is scheduled for the Oct. 16 issue of ACS' Chemistry of Materials.


Story Source:

The above story is based on materials provided by American Chemical Society. Note: Materials may be edited for content and length.


Cite This Page:

American Chemical Society. "Targeting Sugars May Revolutionize Treatment Of Bone Disorders." ScienceDaily. ScienceDaily, 10 October 2007. <www.sciencedaily.com/releases/2007/10/071008093002.htm>.
American Chemical Society. (2007, October 10). Targeting Sugars May Revolutionize Treatment Of Bone Disorders. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2007/10/071008093002.htm
American Chemical Society. "Targeting Sugars May Revolutionize Treatment Of Bone Disorders." ScienceDaily. www.sciencedaily.com/releases/2007/10/071008093002.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins